glp-1 weight loss clinical trials GLP-1R Agonists for Frontiers | The agony and

A review published in Diabetes, Obesity and Metabolism found that semaglutide reduced the rate of gastric emptying by up to 27% compared to placebo

Despite demonstrating robust glycemic efficacy, both agents were eventually discontinued due to distinct tolerability and safety concerns, diverging in severity and clinical implications

[1] [2] The weight reduction and improved insulin sensitivity contribute to favorable changes across multiple cardiometabolic risk factors

While research continues to evolve, these medications offer possibilities for addressing multiple health challenges simultaneously through their unique action on brain reward pathways